2018
DOI: 10.22489/cinc.2018.359
|View full text |Cite
|
Sign up to set email alerts
|

Atrial Rotor Modulation by Localized Dofetilide Application: An In Silico Study

Abstract: The rotor ablation has gained favor in recent years to treat chronic atrial fibrillation (CAF). However, it may cause complications in patients and the results remain suboptimal. Besides, antiarrhythmic drugs for the management of AF are not sufficiently effective and can cause significant cardiac and extracardiac side effects. To reduce the risk and increase the effectiveness, a rotor modulation via the localized release of dofetilide is proposed through an in silico study. A computational model of two-dimens… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…An amount of 0.16 mg/mL PPNP biocompatible concentration encapsulated 19.38 + 0.07 and 57.52 ± 0.09 μM, and photoreleased 98.71 and 97.12% of the Nile red and dofetilide hydrophobic drugs, respectively ( Figure 7 and Table 5 ), upon UV irradiation exposure ( Figure 7 (Cb,E)) by azobenzene-based PPNP trans–cis photoisomerization ( Figure 7 D). The delivered dofetilide antiarrhythmic drug depicted a therapeutic concentration with release-accelerated kinetics for possible atrial fibrillation treatment, as established in a previously reported work (5 μM of dofetilide) [ 41 ]. Then, lower PPNP concentrations were safe and valuable for biomedical applications such as drug delivery, intracellular diagnosis, photodynamic therapy, and theragnosis, among others.…”
Section: Discussionmentioning
confidence: 73%
“…An amount of 0.16 mg/mL PPNP biocompatible concentration encapsulated 19.38 + 0.07 and 57.52 ± 0.09 μM, and photoreleased 98.71 and 97.12% of the Nile red and dofetilide hydrophobic drugs, respectively ( Figure 7 and Table 5 ), upon UV irradiation exposure ( Figure 7 (Cb,E)) by azobenzene-based PPNP trans–cis photoisomerization ( Figure 7 D). The delivered dofetilide antiarrhythmic drug depicted a therapeutic concentration with release-accelerated kinetics for possible atrial fibrillation treatment, as established in a previously reported work (5 μM of dofetilide) [ 41 ]. Then, lower PPNP concentrations were safe and valuable for biomedical applications such as drug delivery, intracellular diagnosis, photodynamic therapy, and theragnosis, among others.…”
Section: Discussionmentioning
confidence: 73%